A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy

A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy

Background: Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a chemotherapy associated with high toxicity rates and variable efficacy. Therefore, it is crucial to identify patients at risk of early progression during treatment. This study aims to explore the potential of a m...

Full description

Bibliographic Details
Main Authors: Casper W.F. van Eijck, Sergio Sabroso-Lasa, Gaby J. Strijk, Dana A.M. Mustafa, Amine Fellah, Bas Groot Koerkamp, Núria Malats, Casper H.J. van Eijck
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Biomarkers
Gene Expression Profiling
folfirinox
Pancreatic Neoplasms
Precision Medicine
Protein Array Analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624000125

Internet

http://www.sciencedirect.com/science/article/pii/S1476558624000125

Similar Items